表紙:CAR-Tの資金調達:ベンチャーキャピタル、IPO、ライセンス契約、事業提携、M&A取引 (2024年)
市場調査レポート
商品コード
1443436

CAR-Tの資金調達:ベンチャーキャピタル、IPO、ライセンス契約、事業提携、M&A取引 (2024年)

CAR-T Funding Report - Venture Capital, IPOs, Licensing Deals, Collaborations, and M&A Transactions, 2024

出版日: | 発行: BioInformant | ページ情報: 英文 207 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
CAR-Tの資金調達:ベンチャーキャピタル、IPO、ライセンス契約、事業提携、M&A取引 (2024年)
出版日: 2024年03月04日
発行: BioInformant
ページ情報: 英文 207 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

エグゼクティブサマリー

CAR-T業界への資金調達は、増えているのではなく、急増しています。当初、この動向は微妙なものでしたが、Kymriah、Yescarta、Tecartus、Breyanzi、Abecma、CarvyktiなどのCAR-T療法が市場に登場し、資金調達ブームを巻き起こしたことで、潮流は大きくなっています。近年、CAR-Tの新興企業は、この再生医療の動向への参入を熱望する投資家から潤沢な資金を得ています。

世界全体では、170以上の企業がCAR-T製品や治療法の開発に携わっています。これらのCAR-T治療企業は、970近い初期段階および後期段階の治療法を開発しています。これらの企業はまた、各種のCAR-T製品候補の開発を進めるために、98件という驚くべき事業協力契約を結んでいます。このうち、33の事業協力案件が財務条件を開示しており、その取引総額は217億米ドルにのぼります。条件を開示していない事業協力案件について試算すると、これら98件の事業協力案件の総額は630億米ドルという驚くべき規模になります。

過去10年間で、CAR-T企業はベンチャーキャピタルから67億米ドルもの投資を受け、インフラや製品パイプラインへの投資を可能にしてきました。同期間中、CAR-T企業は技術基盤、臨床試験プログラム、企業努力を強化するため、IPO資金を通じて58億米ドルの資金を調達しました。

417,801件以上の特許記録と、4,024件の付与特許を持つこの新興業界では、大手製薬企業が既存の特許所有者から権利をライセンシングすることで、CAR-T分野への参入を目指す傾向が強まっています。このため、過去10年間のCAR-Tライセンス取引の総額は39億米ドルに上り、この総額は今後10年間で大幅に拡大すると予想されています。

当レポートで分析した様々な種類の資金調達 (CAR-T業界のIPO・ライセンス契約、事業提携、戦略的パートナーシップ、共同開発契約、M&A取引など) の中で、M&A取引が最も大きな財務比率を占めており、過去10年間で959億米ドルという驚異的な金額を占めています。

歴史の浅いCAR-T業界にとって、財務条件を報告したこれらの様々な取引を通じて、1,282億5,000万米ドル以上を調達したことは驚異的な業績です。さらに、84件のCAR-Tライセンス契約のうち59件、98件の事業協力契約のうち65件、27件のM&A案件のうち11件は、取引額を開示していません。このため、取引額が開示されていないすべての取引について概算を算出すると、その総額は2,400億米ドルという途方もない額になります。

現在、米国FDAによって承認されているCAR-T療法は以下の6つです:

  • チサゲンレクロイセル-T (Kymriah)
  • アクシカブタジェン・シロロイセル (Yescarta)
  • ブレクスカブタジェン・オートロイセル (Tecartus)
  • リゾカブタジェン・マラロイセル (Breyanzi)
  • イデカブタジェン・ビクルーセル (Abecma)
  • チルタカブタジェン・オートロイセル (Carvykte)

上記のCAR-T療法の多くは、他の規制当局 (欧州・中国・インドなど) によって承認されています。CAR-Tの承認は世界規模で加速しているため、このリストはすべてを網羅しているわけではありません。ClinicalTrials.govによると、臨床開発段階にあるCAR-Tプログラムは706件もあります。

当レポートでは、世界のCAR-T細胞治療の分野における資金調達の動向について分析し、全体的な取引件数・取引額の推移や、各種形態別 (資金調達ラウンド、IPO、M&A取引、共同開発契約、戦略的パートナーシップなど) の詳細動向、主要企業78社の取引動向、業界全体の主な促進要因などを調査しております。

目次

第1章 エグゼクティブサマリー

第2章 世界のCAR-T細胞療法の商業化

  • CAR-T細胞療法による治療を受けた患者の総数:年別 (2017~2023年)
  • FDA承認のCAR-T療法によって生み出された総売上収益 (2017~2023年)
  • FDA承認のCAR-T療法の定価

第3章 CAR-T業界の資金調達イベント

  • CAR-T業界のベンチャーキャピタルの融資イベント
    • CAR-T企業が調達したベンチャーキャピタルの総額 (2014~2023年)
    • CAR-T企業が調達したベンチャーキャピタル資金:前年との比較
    • CAR-T企業が調達したベンチャーキャピタル (計78回分の資本調達):取引条件と金額

第4章 CAR-T細胞療法企業が調達したIPO資金

  • CAR-T企業が調達したIPO資金:取引条件と金額
    • Juno Therapeutics
    • Cellular Biomedicine Group
    • Xenetic Biosciences
    • Cellular Biomedicine Group
    • Autolus Therapeutics
    • Allogene Therapeutics
    • Precision BioSciences
    • Atara Biotherapeutics
    • Xenetic Biosciences
    • Cabaletta Bio
    • Atara Biotherapeutics
    • Legend Biotech
    • Mustang Bio
    • JW Therapeutics
    • Atara Biotherapeutics
    • Gracell Biotechnologies
    • Vor Biopharma
    • Adicet Bio
    • CARsgen Therapeutics
    • Xenetic Biosciences
    • Caribou Biosciences
    • Celyad Oncology
    • Adicet Bio
    • Legend Biotech
    • Kyverna Therapeutics
    • Arcellx
    • TC Biopharm
    • Celularity
    • TC BioPharm
    • Precision Biosciences
    • Legend Biotech
    • TC Biopharm
    • Vor Biopharma
    • Precigen
    • TC Biopharm
    • Celularity
    • Legend Biotech
    • Coeptis Therapeutics
    • Caribou Biosciences

第5章 世界各国でのCAR-Tライセンス契約の実施状況

  • 世界各国のCAR-Tライセンス契約の総額
    • CAR-Tライセンス契約の概要:取引条件と金額

第6章 CAR-T事業協力取引

  • CAR-T関連の事業協力 (コラボレーション) 取引 (2013~2023年)
    • 2013年から2023年に締結されたCAR-T事業協力契約の概要

第7章 CAR-T業界の企業合併・買収 (M&A) 取引

  • 世界各国でCAR-T細胞療法分野にて実行されたM&A取引:取引条件と金額
    • Cellular Biomedicine および Chinese PLA General Hospital
    • Gilead Sciences および Kite Pharma
    • Gilead Sciences および Cell Design Labs
    • Novartis および Endocyte
    • Bristol Myers Squibb および Celgene
    • Xenetic Biosciences および Scripps Research Institute
    • Astellas Pharma および Xyphos Biosciences
    • BioNTech および Neon Therapeutics
    • resTORbio および Adicet Bio
    • Century Therapeutics および Empirica Therapeutics
    • Celularity および GX Acquisition
    • Cellular Biomedicine および CBMG Merger Sub
    • Amgen および Five Prime Therapeutics
    • BioNTech および Kite
    • ImmPACT Bio および Kalthera
    • Kiromic Biopharma および InSilico Solutions
    • Allogene Therapeutics および Antion Biosciences
    • FUJIFILM Corporation および Atara Biotherapeutics
    • FUJIFILM Corporation および Atara Biotherapeutics
    • Galapagos および CellPoint/AboundBio
    • Atossa Therapeutics および Dynamic Cell Therapies
    • Kite および Tmunity Therapeutics
    • Janssen および Cellular Biomedicine
    • Mustang Bio および uBriGene Biosciences
    • Precision Biosciences および Imugene
    • Oxford Biomedica および Institut Merieux
    • Clade Therapeutics および Gadeta
    • Kyowa Kirin および Orchard Therapeutics

第8章 資金調達イベントに関与するCAR-T企業のプロファイル

  • AdAlta Ltd.
  • Adicet Bio
    • ガンマデルタT細胞
  • AffyImmune Therapeutics, Inc.
    • アフィニティ調整CAR
    • リアルタイムCAR-T細胞モニタリング
  • Allogene Therapeutics
    • AlloCAR-T
  • Alpha Biopharma
  • Antion Biosciences
    • miCAR-T技術
  • Arcellx, Inc.
    • D-ドメイン技術
    • ddCAR
    • ARC-SparX
  • Arsenal Biosciences, Inc.
  • Astellas Pharma, Inc.
    • 提携
  • Atara Biotherapeutics
  • Autolus Therapeutics PLC
  • AvenCell Therapeutics, Inc.
    • 自在に切り替え可能なCARプラットフォーム
  • Beam Therapeutics
  • Bellicum Pharmaceuticals, Inc.
    • GoCAR技術
    • CaspaCIDe技術
  • Biosceptre
    • ユニークなターゲット:nfP2X7 
  • BioNTech SE
    • ネオアンチゲン・ベースのT細胞治療プラットフォーム
  • bluebird bio
  • Cargo Therapeutics
  • Caribou Biosciences, Inc.
    • 次世代CRISR技術
    • CAR-T治療プラットフォーム
  • Carina Biotech
    • LGR5 CAR-Tプログラム
  • CARsgen Therapeutics Holdings Limited
    • CycloCAR
    • THANK-uCAR
  • Cartherics Pty Ltd
    • CarthericsのCAR-T細胞
  • Cellares
    • Cell Shuttle
  • Cellectis
  • Cellular Biomedicine Group
  • Celularity, Inc.
    • プラセンタの力
    • NK細胞プラットフォーム
    • T細胞プラットフォーム
    • エクソソームプラットフォーム
  • Celyad Oncology
    • shRNAプラットフォーム
    • shARCプラットフォーム
  • Chengdu Usano Biotechnology Co., ltd. (Ucello)
  • Chimeric Therapeutics, Ltd.
    • CLTX CAR-T
    • CDH17 CAR-T
  • Clade Therapeutics
    • プラットフォーム技術
  • Coeptis Therapeutics, Inc.
    • SNAP-CAR
  • CRISPR Therapeutics
  • Currus Biologics
    • BEAT技術
  • CytoMed Therapeutics Ltd.
    • CAR-yデルタ-T細胞
  • Dynamic Cell Therapies, Inc.
    • プラットフォーム技術
  • Elicera Therapeutics
  • Galapagos NV
  • Gracell Biotechnologies
    • FasTCAR
    • TruUCAR
    • SMART CART
  • EXUMA Biotech Corp.
    • TMR CAR-T技術
  • IASO Biotherapeutics
    • 技術プラットフォーム
  • Immuneel Therapeutics, Pvt., Ltd.
  • ImmPACT Bio
    • CD19/20二重特異性CAR
    • TGF-B
  • Inceptor Bio
    • CAR-M療法
  • Interius BioTherapeutics
  • Invectys, Inc.
    • IVS-3001:抗HLA-G CAR-T細胞
  • Juventas Cell Therapy, Ltd.
  • JW Therapeutics
    • Carteyva (レルマセル)
  • Galapagos NV
    • プラットフォーム技術
  • Kite Pharma (Gilead)
  • Kyverna Therapeutics
    • 「よりスマートな」CAR-T細胞
  • Legend Biotech
    • Carvykti
  • Leucid Bio, Ltd.
    • ラテラルCARプラットフォーム
  • Luminary Therapeutics
    • ガンマ2.0+プラットフォーム
  • Lupagen, Inc.
    • サイドCAR-T送達システム
  • MaxCyte, Inc.
  • Minerva Biotechnologies
  • Mustang Bio, Inc.
  • Noile-Immune Biotech
    • PRIME Technology
  • Novartis AG
    • Kymriahの承認
  • OneChain Immunotherapeutics
  • Oncternal Therapeutics, Inc
  • ROR1 
  • OriCell Therapeutics
    • OriCAR
  • Oxford Biomedica PLC
    • Lentivectorプラットフォーム
    • アデノ随伴ウイルスプラットフォーム
  • Pepromene Bio, Inc.
    • BAFFR CAR-T細胞
  • PersonGen Bio Therapeutics (Suzhou) Co., Ltd
  • Poseida Therapeutics, Inc.
    • PiggyBacプラットフォーム
    • CasCLOVERプラットフォーム
  • Precigen, Inc.
    • UltraCAR-Tプラットフォーム
  • Precision BioSciences
    • ARCUS遺伝子編集プラットフォーム
  • Prescient Therapeutics
    • OmniCAR
    • CellPryme-M
    • CellPryme-A
  • Simnova Biotherapeutics
    • BiTE CAR-Tプラットフォーム
  • SOTIO Biotech B.V.
  • TC BioPharm
    • ガンマデルタT細胞
    • T細胞バンク
    • Co-Stim CAR-T
  • Umoja Biopharma
    • VivoVecのin vivo遺伝子送達
    • RACR誘導性細胞傷害性リンパ球 (iCIL)
    • RACR/CAR in vivo細胞プログラミング
    • TumorTag
  • Verismo Therapeutics, Inc.
    • KIR-CARプラットフォーム
  • Vor Biopharma
  • Wugen, Inc.
  • Xenetic Biosciences, Inc.
    • XBIO-020:DNase I 装甲CAR-T
  • Xyphos Biosciences, Inc.
    • covertibleCAR技術

図の一覧

表の一覧

目次

EXECUTIVE SUMMARY:

CAR-T industry funding isn't gaining traction, it is surging. At first, the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus, Breyanzi, Abecma, and Carvykti have reached the marketplace and created a funding boom. In recent years, CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine.

Worldwide, more than 170 companies are engaged in developing CAR-T products and therapies. These CAR-T therapy companies have developed nearly 970 early and late-stage therapies. These companies have also signed an incredible 98 collaboration deals to progress the development of various CAR-T product candidates. Of these, 33 collaboration deals have disclosed their financial terms, which account for a total of $21.7 billion in transactions. If an estimate is made for the collaboration deals that have not disclosed their terms, the total value of these 98 collaboration deals would be in the range of an astonishing $63 billion.

Over the past decade, CAR-T companies have also attracted venture capital investments worth an incredible $6.7 billion, enabling these CAR-T companies to invest in their infrastructure and product pipelines. During the same period, CAR-T companies raised an impressive $5.8 billion through IPO funding to strengthen their technology platforms, clinical trial programs, and corporate efforts.

Within this nascent industry, with over 417,801 patent records and 4,024 granted patents, large pharma has increasingly been seeking to enter the CAR-T field by licensing rights from existing patent owners. Thus, the total value of CAR-T licensing deals over the past decade accounts for another $3.9 billion in transactions and this total is expected to expand substantially in the coming decade.

Among the various financing types analyzed in this report-which include CAR-T industry IPOs, licensing deals, collaborations, strategic partnerships, co-development agreements, and M&A deals-M&A deals constitute the largest financial percentage, accounting for an astounding $95.9 billion over the past decade.

For the nascent CAR-T industry, it is a phenomenal achievement to raise more than $128.25 billion through these various deals that have reported their financial terms. Additionally, 59 of 84 CAR-T licensing deals, 65 of the 98 CAR-T collaboration deals, and 11 of the 27 CAR-T industry M&A deals did not disclose the value of their transactions. Thus, if an approximate estimate is calculated for all deals of undisclosed values, the total value would be a staggering $240 billion.

At present, six CAR-T therapies have been approved by U.S. FDA, including:

  • Tisagenlecleucel-T (Kymriah)
  • Axicabtagene ciloleucel (Yescarta)
  • Brexucabtagene autoleucel (Tecartus)
  • Lisocabtagene maraleucel (Breyanzi)
  • Idecabtagene vicleucel (Abecma)
  • Ciltacabtagene autoleucel (Carvykte)

Many of the CAR-T therapies above have been approved by other regulatory agencies, most commonly for use within the EU. Numerous CAR-T therapies have reached commercialization in other regions as well, such as Relma-cel's (Relmacabtagene) and Yikaida's (Axicabtagene ciloleucel) approval from the NMPA in China, Ebvallo's (tabelecleucel) approval from the European Commission, Actaly-cel's (Actalycabtagene autoleucel) in India, and Fucaso's (Equecabtagene autoleucel) approval in China, for example. This list is not exhaustive because CAR-T approvals are accelerating on a global scale. According to ClinicalTrials.gov, there are also an incredible 706 CAR-T programs that are in clinical phases of development.

This CAR-T market funding report summarizes all types of investments flowing into CAR-T companies worldwide, including financing rounds, IPOs, M&A transactions, co-development agreements, and strategic partnerships. Additionally, it profiles 78 leading competitors who have been involved with these CAR-T industry funding events. Of course, it aggregates these numbers so you can understand the global impact of these funding events and how they are propelling rapid growth of the CAR-T sector at large.

It features the following information for the CAR-T cell therapy industry:

  • Financing Rounds
  • IPOs
  • Asset Agreements
  • Strategic Partnerships
  • Co-Development Agreements
  • M&A Transactions
  • Companies Profiles for CAR-T Market Competitors

You can use it to:

  • 1. Quantify CAR-T industry investments
  • 2. Identify well-capitalized companies
  • 3. Scout potential partnerships and alliances
  • 4. Understand partnerships and co-development programs for CAR-T technologies
  • 5. Identify M&A activity within the CAR-T industry

In summary, there have been hundreds of billions of dollars in financial transactions completed by CAR-T companies in recent years. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. GLOBAL COMMERCIALIZATION OF CAR-T CELL THERAPIES

  • 2.1. Total Number of Patients Treated with CAR-T Cell Therapies by Year, 2017-2023
  • 2.2. Total Sales Revenues Generated by FDA-Approved CAR-T Therapies, 2017-2023
  • 2.3. List Prices of FDA-Approved CAR-T Therapies

3. CAR-T INDUSTRY FUNDING EVENTS

  • 3.1. CAR-T Industry Venture Capital Financing Events
    • 3.1.1. Total Venture Capital Raised by CAR-T Companies, 2014 - 2023
    • 3.1.2. Year-Over-Year Comparison of Venture Capital Funding Raised by CAR-T Companies
    • 3.1.3. Venture Capital Raised by CAR-T Companies (78 Capital Raises) - Deal Terms & Values
      • 3.1.3.1. Bellicum Pharmaceuticals
      • 3.1.3.2. CRISPR Therapeutics
      • 3.1.3.3. Autolus
      • 3.1.3.4. Cellular Biomedicine Group
      • 3.1.3.5. Adicet Bio
      • 3.1.3.6. Autolus Limited
      • 3.1.3.7. Cellular Biomedicine Group
      • 3.1.3.8. JW Therapeutics
      • 3.1.3.9. Carina Biotech
      • 3.1.3.10. PeproMene Bio
      • 3.1.3.11. Precision BioSciences
      • 3.1.3.12. Cabaletta Bio
      • 3.1.3.13. Vor Biopharma
      • 3.1.3.14. Gracel Biotechnologies
      • 3.1.3.15. Mustang Bio
      • 3.1.3.16. Poseida Therapeutics
      • 3.1.3.17. BioNTech
      • 3.1.3.18. Adicet Bio
      • 3.1.3.19. Kyverna Therapeutics
      • 3.1.3.20. EXUMA Biotech
      • 3.1.3.21. IASO Biotherapeutics
      • 3.1.3.22. Legend Biotech
      • 3.1.3.23. JW Therapeutics
      • 3.1.3.24. Vor Pharma
      • 3.1.3.25. ImmPACT Bio
      • 3.1.3.26. Synthekine
      • 3.1.3.27. Gracell Biotechnologies
      • 3.1.3.28. CARsgen Therapeutics
      • 3.1.3.29. Umoja Biopharema
      • 3.1.3.30. Juventas Cell Therapy
      • 3.1.3.31. Celyad Oncology
      • 3.1.3.32. Artiva Biotherapeutics
      • 3.1.3.33. Caribou Biosciences
      • 3.1.3.34. Biosceptre
      • 3.1.3.35. Noile-Immune Biotech
      • 3.1.3.36. Arcellx
      • 3.1.3.37. Cellares Corporation
      • 3.1.3.38. Interius BioTherapeutics
      • 3.1.3.39. Synthekine
      • 3.1.3.40. Umoja Biopharma
      • 3.1.3.41. Wugen
      • 3.1.3.42. Mnemo Therapeutics
      • 3.1.3.43. AvenCell
      • 3.1.3.44. Currus Biologics
      • 3.1.3.45. Juventas Cell Therapy
      • 3.1.3.46. Carina Biotech
      • 3.1.3.47. IASO Biotherapeutics
      • 3.1.3.48. Cellular Biomedicines
      • 3.1.3.49. AffyImmune Therapeutics
      • 3.1.3.50. Leucid Bio
      • 3.1.3.51. Clade Therapeutics
      • 3.1.3.52. SOTIO Biotech
      • 3.1.3.53. EXUMA Biotech
      • 3.1.3.54. ImmPACT Bio
      • 3.1.3.55. Kyverna Therapeutics
      • 3.1.3.56. Ucello Therapeutics
      • 3.1.3.57. Mustang Bio
      • 3.1.3.58. Wugen
      • 3.1.3.59. Inceptor Bio
      • 3.1.3.60. Tessa Therapeutics
      • 3.1.3.61. Immuneel Therapeutics
      • 3.1.3.62. OriCell Therapeutics
      • 3.1.3.63. Carina Biotech
      • 3.1.3.64. Juventas Cell Therapy
      • 3.1.3.65. Arsenal Biosciences
      • 3.1.3.66. Synthekine
      • 3.1.3.67. IASO Biotherapeutics
      • 3.1.3.68. MPC Therapeutics
      • 3.1.3.69. OriCell Therapeutics
      • 3.1.3.70. Verismo Therapeutics
      • 3.1.3.71. Cargo Therapeutics
      • 3.1.3.72. OneChain Immunotherapeutics
      • 3.1.3.73. Caribou Biosciences
      • 3.1.3.74. Verismo Therapeutics
      • 3.1.3.75. Kyverna Therapeutics
      • 3.1.3.76. Gracell Biotechnologies
      • 3.1.3.77. Cellares
      • 3.1.3.78. Celyad Oncology

4. IPO FUNDING RAISED BY CAR-T CELL THERAPY COMPANIES

  • 4.1. IPO Funds Raised by CAR-T Compamies - Deal Terms & Values
    • 4.1.1. Juno Therapeutics
    • 4.1.2. Cellular Biomedicine Group
    • 4.1.3. Xenetic Biosciences
    • 4.1.4. Cellular Biomedicine Group
    • 4.1.5. Autolus Therapeutics
    • 4.1.6. Allogene Therapeutics
    • 4.1.7. Precision BioSciences
    • 4.1.8. Atara Biotherapeutics
    • 4.1.9. Xenetic Biosciences
    • 4.1.10. Cabaletta Bio
    • 4.1.11. Atara Biotherapeutics
    • 4.1.12. Legend Biotech
    • 4.1.13. Mustang Bio
    • 4.1.14. JW Therapeutics
    • 4.1.15. Atara Biotherapeutics
    • 4.1.16. Gracell Biotechnologies
    • 4.1.17. Vor Biopharma
    • 4.1.18. Adicet Bio
    • 4.1.19. CARsgen Therapeutics
    • 4.1.20. Xenetic Biosciences
    • 4.1.21. Caribou Biosciences
    • 4.1.22. Celyad Oncology
    • 4.1.23. Adicet Bio
    • 4.1.24. Legend Biotech
    • 4.1.25. Kyverna Therapeutics
    • 4.1.26. Arcellx
    • 4.1.27. TC Biopharm
    • 4.1.28. Celularity
    • 4.1.29. TC BioPharm
    • 4.1.30. Precision Biosciences
    • 4.1.31. Legend Biotech
    • 4.1.32. TC Biopharm
    • 4.1.33. Vor Biopharma
    • 4.1.34. Precigen
    • 4.1.35. TC Biopharm
    • 4.1.36. Celularity
    • 4.1.37. Legend Biotech
    • 4.1.38. Coeptis Therapeutics
    • 4.1.39. Caribou Biosciences

5. CAR-T LICENSING DEALS EXECUTED GLOBALLY

  • 5.1. Total Value of CAR-T Licensing Deals Worldwide
    • 5.1.1. Descriptions of CAR-T Licensing Deals - Deal Terms & Values
      • 5.1.1.1. Cellectis & Ohio State University
      • 5.1.1.2. bluebird bio & Five Prime Therapeutics
      • 5.1.1.3. Poseida Therapeutics & Janssen Biotech
      • 5.1.1.4. bluebird bio & ViroMed
      • 5.1.1.5. Bellicum Pharmaceuticals & Astellas Pharma
      • 5.1.1.6. CRISPR Therapeutics & MaxCyte
      • 5.1.1.7. bluebird bio & Novartis
      • 5.1.1.8. Novartis & Celyad
      • 5.1.1.9. TC Biopharm & University College London (UCL)
      • 5.1.1.10. Mustang Bio & Fred Hutchinson Cancer Research Center
      • 5.1.1.11. Mustang Bio & Harvard University
      • 5.1.1.12. bluebird bio & TC Biopharm
      • 5.1.1.13. Janssen Biotech & Legend Biotech
      • 5.1.1.14. Autolus & UCL Business
      • 5.1.1.15. Otsuka Pharmaceutical & Osaka University
      • 5.1.1.16. Cellular Biomedicine & Novartis
      • 5.1.1.17. CRISPR Therapeutics & MaxCyte
      • 5.1.1.18. Wugen & Washington University
      • 5.1.1.19. Atara Biotherapeutics & Memorial Sloan Kettering Cancer Center
      • 5.1.1.20. bluebird bio & Inhibrx
      • 5.1.1.21. Autolus Therapeutics & Noile-Immune Biotech
      • 5.1.1.22. Vor Biopharma & MaxCyte
      • 5.1.1.23. Juno Therapeutics & Oxford Biomedica
      • 5.1.1.24. Allogene Therapeutics & MaxCyte
      • 5.1.1.25. Kite & Teneobio
      • 5.1.1.26. Legend Biotech & Noile-Immune Biotech
      • 5.1.1.27. Caribou Biosciences & MaxCyte
      • 5.1.1.28. Prescient Therapeutics & University of Pennsylvania
      • 5.1.1.29. Minerva Biotechnologies & Memorial Sloan Kettering Cancer Center
      • 5.1.1.30. Luminary Therapeutics & Case Western Reserve University
      • 5.1.1.31. Beam Therapeutics & Oxford Biomedica
      • 5.1.1.32. SOTIO Biotech & Unum Therapeutics
      • 5.1.1.33. Vor Biopharma & Metagenomi
      • 5.1.1.34. Chimeric Therapeutics & City of Hope
      • 5.1.1.35. Vor Biopharma & Arbor Biotechnologies
      • 5.1.1.36. Immuneel Therapeutics & Hospital Clinic de Barcelona (HCB)
      • 5.1.1.37. Vor Biopharma & National Cancer Institute (NCI)
      • 5.1.1.38. Caribou Biosciences & Memorial Sloan Kettering Cancer Center
      • 5.1.1.39. Carina Biotech & Bionomics
      • 5.1.1.40. Atara Biotherapeutics & Bayer
      • 5.1.1.41. Cellectis & SIRION Biotech
      • 5.1.1.42. Eli Lilly & Precision BioSciences
      • 5.1.1.43. AbbVie & Caribou Biosciences
      • 5.1.1.44. Luminary Therapeutics & Bio-Techne Corporation
      • 5.1.1.45. Wugen & HCW Biologics
      • 5.1.1.46. Alpha Biopharma & Wugen
      • 5.1.1.47. Servier & Precision Biosciences
      • 5.1.1.48. Dr. Reddy's Laboratories & Pregene Biopharma
      • 5.1.1.49. Celularity & MaxCyte
      • 5.1.1.50. BioNTech & Takara Bio
      • 5.1.1.51. Bellicum Pharmaceuticals & UNC Lineberger
      • 5.1.1.52. Mustang Bio & Mayo Clinic
      • 5.1.1.53. Precision Biosciences & Tiziana Sciences
      • 5.1.1.54. Arcellx & Oxford Biomedica
      • 5.1.1.55. Carina Biotech & BayPAT
      • 5.1.1.56. Inceptor Bio & University of California
      • 5.1.1.57. Rebirthel & Otsuka Pharmaceutical
      • 5.1.1.58. Kyverna Therapeutics & National Institutes of Health (NIH)
      • 5.1.1.59. Intellia Therapeutics & Kyverna Therapeutics
      • 5.1.1.60. Antion Biosciences & Allogene Therapeutics
      • 5.1.1.61. Sana Biotechnology & IASO Biotherapeutics
      • 5.1.1.62. CellPoint & Pregene
      • 5.1.1.63. Xenetic Biosciences
      • 5.1.1.64. GO Therapeutics
      • 5.1.1.65. LG Chem & MaxCyte
      • 5.1.1.66. Roche & Poseida Therapeutics
      • 5.1.1.67. Chugai Pharmaceutical & Noile-Immune Biotech
      • 5.1.1.68. Beam Therapeutics & Orbital Therapeutics
      • 5.1.1.69. Undisclosed Company & Oxford Biomedica
      • 5.1.1.70. Coeptis Therapeutics & University of Pittsburgh
      • 5.1.1.71. Cabaletta Bio & IASO Biotherapeutics
      • 5.1.1.72. Inceptor Bio & Avectas
      • 5.1.1.73. Kite Pharma & Refuge Biotechnologies
      • 5.1.1.74. Kite Pharma & Arcellx
      • 5.1.1.75. Cabaletta Bio & Autolus Therapeutics
      • 5.1.1.76. Precigen & Alaunos
      • 5.1.1.77. Leucid Bio & ImaginAb
      • 5.1.1.78. Affini-T Therapeutics & MSK
      • 5.1.1.79. Shunxi Holding & Cartherics
      • 5.1.1.80. Janssen Biotech & Cellular Biomedicine
      • 5.1.1.81. Astellas Pharma & Poseida Therapeutics
      • 5.1.1.82. Imugene & Precision Biosciences
      • 5.1.1.83. Cabaleta Bio & Oxford Biomedica
      • 5.1.1.84. Kyverna Therapeutics & Oxford Biomedica
      • 5.1.1.85. Coeptis Therapeutics & Univerdity of Pittsburgh

6. CAR-T COLLABORATION DEALS

  • 6.1. CAR-T Collaboration Deals between 2013 and 2023
    • 6.1.1. Descriptions of CAR-T Collaboration Deals Signed 2013 to 2023
      • 6.1.1.1. bluebird Bio & Celgene Corporation
      • 6.1.1.2. Pfizer, Inc. & Cellectis
      • 6.1.1.3. Amgen & Kite Pharma
      • 6.1.1.4. Five Prime Therapeutics & bluebird bio
      • 6.1.1.5. Celgene & Juno Therapeutics
      • 6.1.1.6. Cellectis & Servier
      • 6.1.1.7. Kite Pharma & Cell Design Labs
      • 6.1.1.8. Kite Pharma & Fosun Pharma
      • 6.1.1.9. Cellular Biomedicine Group & GE Healthcare Life Sciences, China
      • 6.1.1.10. Novartis & bluebird bio & Celyad
      • 6.1.1.11. Mustang Bio & Harvard University & Beth Israel Deaconess Medical
      • 6.1.1.12. Jenssen Biotech & Legend Biotech
      • 6.1.1.13. PersonGen & Anke Cellular Therapeutics & Miltenyi Biotec
      • 6.1.1.14. Kite Pharma & Sangamo Therapeutics
      • 6.1.1.15. bluebird bio & Celgene Corporation
      • 6.1.1.16. AbbVie & Calibr
      • 6.1.1.17. Novartis & Fraunhofer IZI
      • 6.1.1.18. Cellular Biomedicine & Novartis
      • 6.1.1.19. Regeneron Pharmaceuticals & bluebird bio
      • 6.1.1.20. Cartherics & ToolGen
      • 6.1.1.21. TC Biopharm & Dublin's Trinity College
      • 6.1.1.22. MaxCyte & Kite Pharma
      • 6.1.1.23. Phanes Therapeutics & Phanes Biopharmaceuticals & Fosun Kite
      • 6.1.1.24. Cellectis SA & Servier Monde
      • 6.1.1.25. MaxCyte & Allogene Therapeutics
      • 6.1.1.26. Fate Therapeutics & Janssen Biotech
      • 6.1.1.27. bluebird bio & Bristol Myers Squibb
      • 6.1.1.28. Xenetic Biosciences & PJSC Pharmsynthez
      • 6.1.1.29. Fate Therapeutics & Baylor College of Medicine
      • 6.1.1.30. Beam Therapeutics & Oxford Biomedica
      • 6.1.1.31. Carina Biotech & Glytherix
      • 6.1.1.32. Chimeric Therapeutics & City of Hope
      • 6.1.1.33. Biosceptre & Carina Biotech
      • 6.1.1.34. Allogene Therapeutics & University of Texas MD Anderson Center
      • 6.1.1.35. Oxford Biomedica & PhoreMost Limited
      • 6.1.1.36. Carina Biotech & Bionomics
      • 6.1.1.37. Bayer AG & Atara Biotherapeutics
      • 6.1.1.38. Oncternal Therapeutics & Karolinska Instituet
      • 6.1.1.39. EXUMA Biotech & Moffitt Cancer Center
      • 6.1.1.40. AbbVie & Caribou Biosciences
      • 6.1.1.41. Cytovia Therapeutics & Cellectis SAS
      • 6.1.1.42. JW Therapeutics & Thermo Fisher Scientific
      • 6.1.1.43. AbbVie & Caribou Biosciences
      • 6.1.1.44. Wugen & Alpha Biopharma
      • 6.1.1.45. Dr. Reddy's Laboratories & Shenzhen Pregene Biopharma
      • 6.1.1.46. Vor Biopharma & Abound Bio
      • 6.1.1.47. Kite Pharma & Fosun Pharmaceutical
      • 6.1.1.48. Takara Bio & BioNTech
      • 6.1.1.49. Vor Biopharma & Janssen Biotech
      • 6.1.1.50. Imugene & Celularity
      • 6.1.1.51. Gracell Biotechnologies & FutureGen Biopharm
      • 6.1.1.52. AdAlta & Carina Biotech
      • 6.1.1.53. Celularity & Oncternal Therapeutics
      • 6.1.1.54. Autolus Therapeutics & Blackstone Life Sciences
      • 6.1.1.55. 4basebio & Leucid Bio
      • 6.1.1.56. Leucid Bio & Lonza
      • 6.1.1.57. Oxford Biomedica & Arcellx
      • 6.1.1.58. Carina Biotech & Bayerische Patentallianz (BayPAT)
      • 6.1.1.59. Intellia Therapeutics & Kyverna Therapeutics
      • 6.1.1.60. Arsenal Biosciences & Bristol Myers Squibb
      • 6.1.1.61. Allogene Therapeutics & Antion Biosciences
      • 6.1.1.62. Transgene & PersonGen BioTherapeutics
      • 6.1.1.63. Immatics & Bristol Myers Squibb
      • 6.1.1.64. Legend Biotech & Janssen Biotech
      • 6.1.1.65. Umoja Biopharma & Lupagen
      • 6.1.1.66. Immatics & Celgene
      • 6.1.1.67. Immatics & Bristol Myers Squibb
      • 6.1.1.68. Umoja Biopharma & TreeFrog Therapeutics
      • 6.1.1.69. Invectys & University of Texas Cancer Center
      • 6.1.1.70. Poseida Therapeutics & Roche
      • 6.1.1.71. Chugai Pharmaceutical & Noile-Immune Biotech
      • 6.1.1.72. Kite Pharma & Arcellx
      • 6.1.1.73. Arsenal Biosciences & Genentech
      • 6.1.1.74. Autolus Therapeutics & Bristol Myers Squibb
      • 6.1.1.75. Inceptor Bio & Avectos
      • 6.1.1.76. JW Therapeutics & 2seventy bio
      • 6.1.1.77. Peter MacCallum Cancer Centre and Cartherics
      • 6.1.1.78. Umoja Biopharma & IASO Biotherapeutics
      • 6.1.1.79. Kite Pharma & Arcellx
      • 6.1.1.80. Ori Biotech & Inceptor Bio
      • 6.1.1.81. Simnova & Orna Therapeutics
      • 6.1.1.82. CARsgen Therapeutics & Huadong Medicine
      • 6.1.1.83. TC Biopharm & University of Texas MD Anderson Cancer Center
      • 6.1.1.84. Kite Pharma & Arcellx
      • 6.1.1.85. Peter MacCallum Cancer Centre & Cartherics
      • 6.1.1.86. Cartherics & Shunxi Holding Group
      • 6.1.1.87. Autolus Therapeutics & Cardinal Health
      • 6.1.1.88. Cartherics & Shunxi
      • 6.1.1.89. Janssen Biotech & Cellular Biomedicine
      • 6.1.1.90. CytoMed Therapeutics & University of Texas MD Anderson Cancer
      • 6.1.1.91. Noile-Immune Biotech & Sysmex
      • 6.1.1.92. GenScript Biotech & T-MAXIMUM Biotech
      • 6.1.1.93. CytoMed Therapeutics & Hangzhou CNK Therapeutics
      • 6.1.1.94. CARsgen Therapeutics & Moderna
      • 6.1.1.95. Cellares & Bristol Myers Squibb
      • 6.1.1.96. Celularity & Regeneron Pharmaceuticals
      • 6.1.1.97. Verily & Kyverna Therapeutics
      • 6.1.1.98. Kyverna Therapeutics & Elevate Bio

7. CAR-T INDUSTRY M&A DEALS (MERGER AND ACQUISITION)

  • 7.1. Globally Executed M&A Deals within the CAR-T Cell Therapy Sector - Terms and Values
    • 7.1.1. Cellular Biomedicine & Chinese PLA General Hospital
    • 7.1.2. Gilead Sciences & Kite Pharma
    • 7.1.3. Gilead Sciences & Cell Design Labs
    • 7.1.4. Novartis & Endocyte
    • 7.1.5. Bristol Myers Squibb & Celgene
    • 7.1.6. Xenetic Biosciences & Scripps Research Institute
    • 7.1.7. Astellas Pharma & Xyphos Biosciences
    • 7.1.8. BioNTech & Neon Therapeutics
    • 7.1.9. resTORbio & Adicet Bio
    • 7.1.10. Century Therapeutics & Empirica Therapeutics
    • 7.1.11. Celularity & GX Acquisition
    • 7.1.12. Cellular Biomedicine & CBMG Merger Sub
    • 7.1.13. Amgen & Five Prime Therapeutics
    • 7.1.14. BioNTech & Kite
    • 7.1.15. ImmPACT Bio & Kalthera
    • 7.1.16. Kiromic Biopharma & InSilico Solutions
    • 7.1.17. Allogene Therapeutics & Antion Biosciences
    • 7.1.17. FUJIFILM Corporation & Atara Biotherapeutics
    • 7.1.18. FUJIFILM Corporation & Atara Biotherapeutics
    • 7.1.19. Galapagos & CellPoint/AboundBio
    • 7.1.20. Atossa Therapeutics & Dynamic Cell Therapies
    • 7.1.21. Kite & Tmunity Therapeutics
    • 7.1.22. Janssen & Cellular Biomedicine
    • 7.1.23. Mustang Bio & uBriGene Biosciences
    • 7.1.24. Precision Biosciences & Imugene
    • 7.1.25. Oxford Biomedica & Institut Merieux
    • 7.1.26. Clade Therapeutics & Gadeta
    • 7.1.27. Kyowa Kirin & Orchard Therapeutics

8. PROFILES OF CAR-T COMPANIES INVOLVED WITH FUNDING EVENTS

  • 8.1. AdAlta Ltd.
  • 8.2. Adicet Bio
    • 8.2.1. Gamma Delta T Cells
  • 8.3. AffyImmune Therapeutics, Inc.
    • 8.3.1. Affinity-Tuned CARs
    • 8.3.2. Real-Time CAR-T Cell Monitoring
  • 8.4. Allogene Therapeutics
    • 8.4.1. AlloCAR-T
  • 8.5. Alpha Biopharma
  • 8.6. Antion Biosciences
    • 8.6.1. miCAR-T Technology
  • 8.7. Arcellx, Inc.
    • 8.7.1. D-Domain Technology
    • 8.7.2. ddCAR
    • 8.7.3. ARC-SparX
  • 8.8. Arsenal Biosciences, Inc.
  • 8.9. Astellas Pharma, Inc.
    • 8.9.1. Partnering
  • 8.10. Atara Biotherapeutics
  • 8.11. Autolus Therapeutics PLC
  • 8.12. AvenCell Therapeutics, Inc.
    • 8.12.1. Universal Switchable CAR Platform
  • 8.13. Beam Therapeutics
  • 8.14. Bellicum Pharmaceuticals, Inc.
    • 8.14.1. GoCAR Technology
    • 8.14.2. CaspaCIDe Technology
  • 8.15. Biosceptre
    • 8.15.1. The Unique Target: nfP2X7
  • 8.16. BioNTech SE
    • 8.16.1. Neoantigen-based T Cell Therapy Platform
  • 8.17. bluebird bio
  • 8.18. Cargo Therapeutics
  • 8.19. Caribou Biosciences, Inc.
    • 8.19.1. Next-Generation CRISR Technology
    • 8.19.1. CAR-T Therapy Platform
  • 8.20. Carina Biotech
    • 8.20.1. LGR5 CAR-T Program
  • 8.21. CARsgen Therapeutics Holdings Limited
    • 8.21.1. CycloCAR
    • 8.21.2. THANK-uCAR
  • 8.22. Cartherics Pty Ltd
    • 8.22.1. Cartherics' CAR-T Cells
  • 8.23. Cellares
    • 8.23.1. Cell Shuttle
  • 8.24. Cellectis
  • 8.25. Cellular Biomedicine Group
  • 8.26. Celularity, Inc.
    • 8.26.1. Power of the Placenta
    • 8.26.2. NK Cell Platform
    • 8.26.3. T Cell Platform
    • 8.26.4. Exosome Platform
  • 8.27. Celyad Oncology
    • 8.27.1. shRNA Platform
    • 8.27.2. shARC Platform
  • 8.28. Chengdu Usano Biotechnology Co., ltd. (Ucello)
  • 8.29. Chimeric Therapeutics, Ltd.
    • 8.29.1. CLTX CAR-T
    • 8.29.2. CDH17 CAR-T
  • 8.30. Clade Therapeutics
    • 8.30.1. Platform Technologies
  • 8.31. Coeptis Therapeutics, Inc.
    • 8.31.1. SNAP-CAR
  • 8.32. CRISPR Therapeutics
  • 8.33. Currus Biologics
    • 8.33.1. BEAT Technology
  • 8.34. CytoMed Therapeutics Ltd.
    • 8.34.1. CAR-yDelta- T Cell
  • 8.35. Dynamic Cell Therapies, Inc.
    • 8.35.1. Platform Technology
  • 8.36. Elicera Therapeutics
  • 8.37. Galapagos NV
  • 8.38. Gracell Biotechnologies
    • 8.38.1. FasTCAR
    • 8.38.2. TruUCAR
    • 8.38.3. SMART CART
  • 8.39. EXUMA Biotech Corp.
    • 8.39.1. TMR CAR-T Technology
  • 8.40. IASO Biotherapeutics
    • 8.40.1. Technology Platforms
  • 8.41. Immuneel Therapeutics, Pvt., Ltd.
  • 8.42. ImmPACT Bio
    • 8.42.1. CD19/20 Bispecific CAR
    • 8.42.2. TGF-B
  • 8.43. Inceptor Bio
    • 8.43.1. CAR-M Therapies
  • 8.44. Interius BioTherapeutics
  • 8.45. Invectys, Inc.
    • 8.45.1. IVS-3001: Anti HLA-G CAR-T Cells
  • 8.46. Juventas Cell Therapy, Ltd.
  • 8.47. JW Therapeutics
    • 8.47.1. Carteyva (relma-cel)
  • 8.48. Galapagos NV
    • 8.48.1. Platform Technology
  • 8.49. Kite Pharma (Gilead)
  • 8.50. Kyverna Therapeutics
    • 8.50.1. "Smarter" CAR-T Cells
  • 8.51. Legend Biotech
    • 8.51.1. Carvykti
  • 8.52. Leucid Bio, Ltd.
    • 8.52.1. Lateral CAR Platform
  • 8.53. Luminary Therapeutics
    • 8.53.1. Gamma 2.0+ Platform
  • 8.54. Lupagen, Inc.
    • 8.54.1. Side CAR-T Delivery System
  • 8.55. MaxCyte, Inc.
  • 8.56. Minerva Biotechnologies
  • 8.57. Mustang Bio, Inc.
  • 8.58. Noile-Immune Biotech
    • 8.58.1. PRIME Technology
  • 8.59. Novartis AG
    • 8.59.1. Approval of Kymriah
  • 8.60. OneChain Immunotherapeutics
  • 8.61. Oncternal Therapeutics, Inc
  • 8.61. ROR1
  • 8.62. OriCell Therapeutics
    • 8.62.1. OriCAR
  • 8.63. Oxford Biomedica PLC
    • 8.63.1. Lentivector Platform
    • 8.63.2. Adeno-Associated Virus Platform
  • 8.64. Pepromene Bio, Inc.
    • 8.64.1. BAFFR CAR-T Cells
  • 8.65. PersonGen Bio Therapeutics (Suzhou) Co., Ltd
  • 8.66. Poseida Therapeutics, Inc.
    • 8.66.1. PiggyBac Platform
    • 8.66.2. CasCLOVER Platform
  • 8.67. Precigen, Inc.
    • 8.67.1. UltraCAR-T Platform
  • 8.68. Precision BioSciences
    • 8.68.1. ARCUS Gene-Editing Platform
  • 8.69. Prescient Therapeutics
    • 8.69.1. OmniCAR
    • 8.69.2. CellPryme-M
    • 8.69.3. CellPryme-A
  • 8.70. Simnova Biotherapeutics
    • 8.70.1. BiTE CAR-T Platform
  • 8.71. SOTIO Biotech B.V.
  • 8.72. TC BioPharm
    • 8.72.1. Gamma Delta T Cells
    • 8.72.2. T Cell Banks
    • 8.72.3. Co-Stim CAR-T
  • 8.73. Umoja Biopharma
    • 8.73.1. VivoVec In Vivo Gene Delivery
    • 8.73.2. RACR-Induced Cytotoxic Lymphocytes (iCIL)
    • 8.73.3. RACR/CAR In Vivo Cell Programming
    • 8.73.4. TumorTag
  • 8.74. Verismo Therapeutics, Inc.
    • 8.74.1. KIR-CAR Platform
  • 8.75. Vor Biopharma
  • 8.76. Wugen, Inc.
  • 8.77. Xenetic Biosciences, Inc.
    • 8.77.1. XBIO-020: DNase I Armored CAR-T
  • 8.78. Xyphos Biosciences, Inc.
    • 8.78.1. covertibleCAR Technology

INDEX OF FIGURES

  • FIGURE 2.1: Sales Revenues of U.S. FDA-Approved CAR-T Therapies, 2017 to 2023
  • FIGURE 3.1: Total Venture Capital (VC) Raised by CAR-T Companies Worldwide, 2014 to 2023
  • FIGURE 4.1: Total IPO Funds Raised by CAR-T Cell Therapy Companies Worldwide, 2014 to 2023

INDEX OF TABLES

  • TABLE 1.1: All Known CAR-T Fundraising Deals Worldwide, 2014 to Present (Trailing 10 Years)
  • TABLE 2.1: Number of Patients Treated with CAR-T Therapies, 2017 - 2023
  • TABLE 3.1: Venture Capital Raised by CAR-T Companies, 2014 to Present (Trailing 10 Years)
  • TABLE 4.1: IPO Funds Raised by CAR-T Companies, 2014 to Present (Trailing 10 Years)
  • TABLE 5.1: CAR-T Licensing Deals Worldwide, 2015 to Present
  • TABLE 6.1: CAR-T Collaboration Deals Signed Worldwide, 2013 to Present (Trailing 10 Years)
  • TABLE 7.1: CAR-T M&A Deals Signed Worldwide, 2015 to Present